文献速递系统性红斑狼疮

系统性红斑狼疮患者中白细胞介素-21-雷帕霉素机制靶点轴通过抑制自噬阻断调节性T细胞分化和功能

Blockade of Treg Cell Differentiation and Function by the Interleukin-21-Mechanistic Target of Rapamycin Axis Via Suppression of Autophagy in Patients With Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Rheumatol · 2018-01-30

研究探讨系统性红斑狼疮(SLE)患者调节性T细胞(Treg)中雷帕霉素机制靶点(mTOR)是否活化及其与Treg耗竭和功能缺陷的关系。结果显示SLE Treg细胞mTORC1和mTORC2活性增高、自噬受损、GATA-3和CTLA-4表达及抑制功能下降;IL-21通过激活mTOR阻断Treg发育,而雷帕霉素阻断mTOR可恢复自噬和Treg功能。

要点

  • SLE患者Treg细胞mTORC1和mTORC2活性增高,自噬、GATA-3和CTLA-4表达及抑制功能降低。
  • IL-21(而非IL-6或IL-17)通过激活mTORC1和mTORC2阻断Treg细胞分化并损害其功能。
  • 雷帕霉素阻断mTOR可增强TGF-β产生、诱导自噬并纠正Treg细胞功能。

核心结论

  • IL-21驱动的mTOR活化是SLE中Treg细胞功能缺陷所基于的自噬不足的药理学可靶向检查点。

研究设计与样本

  • 研究比较SLE患者与年龄和性别匹配的女性健康对照者,检测T细胞中mTORC1和mTORC2活性。
  • 在IL-6、IL-17和IL-21存在下评估naive CD4+ T细胞向Treg细胞极化。
  • 通过分选CD4+CD25+ Treg细胞对自体CD4+CD25-应答T细胞增殖的影响测定其抑制功能。
  • 用流式细胞术监测Treg细胞FoxP3、GATA-3和CTLA-4表达,用免疫印迹检测轻链3脂化评估自噬。
  • 通过雷帕霉素处理评估mTOR阻断对Treg细胞功能的影响。

主要发现

  • SLE Treg细胞mTORC1和mTORC2活性增高,而自噬、GATA-3和CTLA-4表达及Treg细胞抑制功能降低。
  • IL-21而非IL-6或IL-17阻断Treg细胞发育,并刺激mTORC1和mTORC2、取消Treg细胞自噬、分化和功能。
  • IL-21选择性限制Treg细胞中GATA-3和CTLA-4表达。
  • 3天雷帕霉素处理阻断mTORC1增强转化生长因子β产生。
  • 4周雷帕霉素处理双重阻断mTORC1和mTORC2诱导自噬、恢复GATA-3和CTLA-4表达并纠正Treg细胞功能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The mechanistic target of rapamycin (mTOR) has become a therapeutic target in systemic lupus erythematosus (SLE). In T cells, mTOR plays a central role in lineage specification, including development of regulatory cells (Treg cells). This study sought to investigate whether mTOR is activated within Treg cells and whether this contributes to the depletion and dysfunction of Treg cells in patients with SLE. METHODS: Activities of mTOR complexes 1 (mTORC1) and 2 (mTORC2) were examined by quantifying phosphorylation of translation initiation factor 4E-binding protein 1, S6 kinase, and Akt in SLE patients relative to age- and sex-matched female healthy control subjects. Polarization of Treg cells from naive CD4+ T cells was assessed in the presence of interleukin-6 (IL-6), IL-17, and IL-21. The suppressor function of sorted CD4+CD25+ Treg cells was measured by determining their impact on the proliferation of autologous CD4+CD25- responder T cells. Treg cell expression of FoxP3, GATA-3, and CTLA-4 was monitored by flow cytometry. Autophagy was assessed using immunoblotting of light chain 3 lipidation. The effect of mTOR blockade was evaluated by testing the impact of rapamycin treatment on Treg cell function. RESULTS: SLE Treg cells exhibited increased activities of mTORC1 and mTORC2, whereas autophagy, the expression of GATA-3 and CTLA-4, and the suppressor function of Treg cells were diminished. IL-21, but not IL-6 or IL-17, blocked the development of Treg cells. IL-21 stimulated mTORC1 and mTORC2, and it abrogated the autophagy, differentiation, and function of Treg cells. Moreover, IL-21 constrained the expression of GATA-3 and CTLA-4 selectively in Treg cells. In turn, blockade of mTORC1 by 3-day rapamycin treatment enhanced transforming growth factor β production, while dual blockade of mTORC1 and mTORC2 by 4-week rapamycin treatment induced autophagy, restored the expression of GATA-3 and CTLA-4, and corrected Treg cell function. CONCLUSION: IL-21-driven mTOR activation is a pharmacologically targetable checkpoint of the deficient autophagy that underlies Treg cell dysfunction in SLE.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Kato H, Perl A. Blockade of Treg Cell Differentiation and Function by the Interleukin-21-Mechanistic Target of Rapamycin Axis Via Suppression of Autophagy in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2018. PMID: 29161463. doi:10.1002/art.40380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。